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Vasoinhibins (Vi) are fragments of the growth hormone/prolactin (PRL) family and have 
antiangiogenic functions in many species. It is considered that Vi derived from PRL 
are involved in the pathogenesis of peripartum cardiomyopathy (PPCM). However, 
the pathogenic mechanism of PPCM, as well as heart angiogenesis, is not yet clear. 
Therefore, the aim of the present study is to clarify whether Vi act directly on angio-
genesis inhibition in heart blood vessels. Endothelial cell viability was decreased by Vi 
treatment in a culture experiment. Furthermore, expression of proangiogenic genes, such 
as vascular endothelial growth factor, endothelial nitric oxide synthase, and VE-cadherin, 
were decreased. On the other hand, apoptotic factor gene, caspase 3, and inflammatory 
factor genes, tumor necrosis factor α and interleukin 6, were increased by Vi treatment. 
In three-dimensional left ventricular wall angiogenesis assay in mice, Vi treatment also 
inhibited cell migration, neovessel sprouting, and growth toward collagen gel. These 
data demonstrate that Vi treatment directly suppresses angiogenesis of the heart and 
support the hypothesis that Vi induce PPCM.
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inTrODUcTiOn
Prolactin (PRL) is a hypophyseal polypeptide hormone in humans that consists of 199 amino acids, 
with a molecular weight of approximately 23 kDa. PRL has many functions in various species and 
has been mainly shown to play roles in lactation, maintenance of pregnancy, maternal behavior 
expression, and angiogenesis promotion. However, an atypical form of PRL, which is cleaved into 
N-terminal 16  kDa fragment, has been shown to have antiangiogenic functions. Since growth 
hormone and placental lactogen also exert antiangiogenic effects when cleaved two-thirds from 
the N-terminal residue (1), these antiangiogenic fragments were named Vasoinhibins (Vi) (2). Vi 
derived from PRL also induce apoptosis by caspase 3 (3) and NF-kB (4), inhibit endothelial prolifera-
tion (5) and migration (6), and impair vasodilation (7).
A recent report showed that the Vi derived from PRL mediate peripartum cardiomyopathy 
(PPCM) (8), which is defined as heart failure presenting between the last month of pregnancy and 
5 months after delivery in mothers with no history of heart failure. The cardinal symptom is dilation 
of the left ventricle, and it can induce maternal death in severe cases. In a PPCM mouse model gener-
ated with cardiomyocyte-specific STAT3 knockout, cardiomyopathy is induced by the increase of left 
Table 1 | specific primers for each gene.
genes Forward reverse Product size (bp)
RNA18S5 GTGGAGCGATTTGTCTGGTTA CGGACATCTAAGGGCATCAC 166
eNOS CAGTTGCTGCCAGGTCTGAT GCTGCTTTGCAGGTTTTCCA 88
VE-cadherin ATGAGATCGTGGTGGAAGCG TGTGTACTTGGTCTGGGTGAAG 84
VEGFA CTCCACCATGCCAAGTGGTC GGGTCTCGATTGGATGGCAG 151
TNF CCTGCTGCACTTTGGAGTGA GAGGGTTTGCTACAACATGGG 125
IL6 GTTCCTGCAGAAAAAGGCAAAGA CAGGAACTCCTTAAAGCTGCG 121
CASP3 TGCATACTCCACAGCACCTG TTTCAGCATGGCACAAAGCG 131
RNA18S5, RNA 18 S ribosomal 5; eNOS, endothelial nitric oxide synthase; VEGFA, vascular endothelial growth factor A; TNF, tumor necrosis factor α; IL6, interleukin 6; CASP3, 
caspase 3.
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ventricular Vi (8). Moreover, Vi cause not only endothelial cell 
but also myocardial damage through microRNA-146a released 
from endothelial cells, which reduces cardiomyocyte metabolic 
activity (9).
However, the direct effect of Vi on heart blood vessels is not 
clear. The purpose of this study was to investigate the direct effect 
of Vi on cardiac angiogenesis.
MaTerials anD MeThODs
hormones
Recombinant Vi was produced in Escherichia coli and purified via 
its His tag (Kitayama Labes, Nagano, Japan) as described previ-
ously (10). This recombinant Vi consisted of the 1 to 145 amino 
acid residues of mouse PRL.
cell culture
Human umbilical vein endothelial cells (HUVECs) and a rat 
cardiomyoblast cell line (H9c2) (11) were obtained from DS 
Pharma Biomedical (Osaka, Japan) and American Type Culture 
Collection (Manassas, VA, USA), respectively. HUVECs 
were maintained in Medium for Normal Human Vascular 
Endothelial Cells (Kohjin Bio, Saitama, Japan) supplemented 
with 2% penicillin/streptomycin (Thermo Fisher Scientific, 
Waltham, MA, USA), and H9c2 cells were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM, Thermo Fisher 
Scientific) supplemented with 10% fetal bovine serum (Thermo 
Fisher Scientific) and 2% penicillin/streptomycin (Thermo 
Fisher Scientific) at 37°C under controlled humidity and 5% 
CO2 atmosphere.
cell Viability assay
Cell viability was evaluated by 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
inner salt (MTS) assay (CellTiter 96® AQueous One Solution Cell 
Proliferation Assay, Promega, Madison, WI, USA). HUVECs and 
H9c2 cells were seeded to the wells of 96-well plates at 6 × 104 
and 1 ×  104 cells/cm2, respectively. After cell adhesion to the 
wells, the culture media were exchanged for media supplemented 
with 0.5, 5, and 50  nM Vi or phosphate-buffered saline (PBS) 
endotoxin-free (AdipoGen, San Diego, CA, USA) as the vehicles. 
After incubation of the plate for 8 or 24 h, MTS was added to 
each well. Then, after incubation of the plate for an additional 2 h 
(total 10 h), 10% SDS was added to each well to stop the reaction. 
Absorbance at 490 nm was measured using a micro plate reader 
(PerkinElmer, Waltham, NJ, USA).
gene expression assay
Human umbilical vein endothelial cells were seeded on a 60-mm 
dish at 1.0 × 104 cells/cm2. After cell adhesion, the culture media 
were changed to media containing 50 nM Vi or its vehicle. After 
incubation for 0, 8, or 24 h, the cells were collected. Total RNA 
was extracted from these cells using an RNeasy mini kit (Qiagen, 
Limburg, The Netherlands). The total RNA was reverse tran-
scribed into cDNA using a QuantiTect Reverse Transcription 
kit (Qiagen) according to the manufacturer’s protocol. The 
cDNA was then used as the template for real-time PCR with 
SYBR select master mix (Thermo Fisher Science) and the 7500 
real-time PCR system (Thermo Fisher Science). Specific primers 
for each gene are presented in Table 1. The expression level of 
internal 18 S ribosomal RNA was used for reference to quantify 
the relative target gene expression levels. The mRNA levels were 
expressed as fold change relative to those of the 0-h culture 
sample.
Three-dimensional collagen gel culture
Four-week-old female C57/BL6 mice were purchased from 
CLEA Japan (Tokyo, Japan). The hearts were removed immedi-
ately after cervical dislocation. The method of in vitro assay for 
angiogenesis of the heart was based on previous reports (12, 13). 
Each heart was washed with PBS, and the left ventricular wall 
was fractionalized on the order of 1 mm3 in ice-cold DMEM. A 
fragment was immediately embedded in collagen gel solution 
that consisted of 5% FBS, 2% penicillin/streptomycin, 1  mg/
ml collagen (Nitta Gelatin, Osaka, Japan), reconstitution buffer 
(Nitta Gelatin), and 30 ng/ml mouse vascular endothelial growth 
factor-164 (mVEGF164, Cell Signaling Technology, Danvers, MA, 
USA) in DMEM. After gelation, the gel was covered with cover 
medium consisting of 5% FBS, 2% penicillin/streptomycin, and 
30  ng/ml mVEGF164 in DMEM. The collagen gel solution and 
cover medium included 100  nM Vi or its vehicle in advance. 
Incubation was performed for 1 week at 37°C in a humidified, 
3% O2, 5% CO2 atmosphere. The cover medium was changed 
every 2 days.
FigUre 1 | effects of vasoinhibins (Vi) on cell viability. Effects of Vi on 
endothelial cell (a) and cardiomyocyte (b) viablity in 10- and 26-h culture. 
The white bar shows absorbance in the control. The light gray bar shows it in 
the 0.5 nM-Vi-treated group, the dark gray bar shows it in the 5 nM-Vi-
treated group, and the black bar shows it in the 50 nM-Vi-treated group. Vi: 
vasoinhibin (n = 3, Mean ± SEM, *P < 0.05, **P < 0.01 vs. control).
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angiogenesis assay in the heart
After incubation, the fragments and gels were fixed in 4% 
paraformaldehyde and used for whole-mount lectin staining. 
After permeabilization with Triton X-100, the fragments and 
gels were immersed with Block Ace (DS Pharma Biomedical, 
Osaka, Japan) and incubated with endothelium-specific lectin 
[fluorescein griffonia (Bandeiraea) simplicifolia lectin I, 
isolectin B4; Vector Laboratories, Burlingame, CA, USA]. Cell 
nuclei were stained with SlowFade Gold antifade reagent with 
DAPI (Invitrogen, Waltham, CA, USA). Three-dimensional 
images were obtained using a confocal laser scanning micro-
scope (Olympus, Tokyo, Japan). To evaluate angiogenesis, the 
number of migrated cells and neovessels and the lengths of 
neovessels were measured using ImageJ software (National 
Institutes of Health, Bethesda, MD, USA). The number of 
migrated cells was calculated by counting cells in the gel. 
The number of neovessels was calculated by counting lectin-
positive vessels that sprouted from the left ventricular fragment 
toward the gel, and the lengths of neovessels were averaged for 
all vessel lengths in the gel. The proportion of lectin-positive 
cells was calculated the positive cell number divided by total 
cell number.
statistical analysis
Numerical data are expressed as means ± SEM. Significance was 
evaluated using Student’s t-test for comparisons between means 
and defined as a P-value <0.05.
ethics statement
The experiment of animal use was carried out in accordance 
with the recommendations of AVMA Guidelines for the 
Euthanasia of Animals: 2013 Edition, American Veterinary 
Medical Association, and the Institutional Animal Care and Use 
Committee of Meiji University that approved the protocol of this 
study (IACUC-13-0013).
resUlTs
In order to evaluate the effects of Vi on cell viability of endothelial 
cells and cardiomyocytes, an MTS assay was performed. After 
10  h incubation, Vi from 0.5 to 50  nM significantly decreased 
endothelial cell viability compared with control. Furthermore, 
cell viability was significantly decreased in 50  nM Vi-treated 
endothelial cell after 26 h incubation (Figure 1A). On the other 
hand, Vi did not have any effect on cardiomyocyte viability 
(Figure 1B).
To analyze the effect of Vi on mRNA expression of endothe-
lial cells, real-time PCR was performed after 8- and 24-h 
incubation (Figure  2). Vi significantly decreased expressions 
of several genes related to angiogenesis (endothelial nitric 
oxide synthase; eNOS, VE-cadherin, and vascular endothelial 
growth factor A; VEGFA) compared with control. Caspase 3 
(CASP3) gene expression, which indicates apoptosis, was sig-
nificantly increased with Vi treatment compared with control. 
Although gene expression of tumor necrosis factor α (TNF) 
was not detected in control after 8- or 24-h incubation, neither 
Vi treatment induced the TNF expression. Interleukin 6 (IL6) 
expression was significantly higher with Vi treatment than with 
control on 8-h incubation.
In order to analyze the antiangiogenic effects of Vi, three-
dimensional heart fragment culture and angiogenesis assays 
were performed. The endothelial marker lectin-positive 
cells were seen in gel matrix and heart fragments (Figure 3). 
Migrations of endothelial marker-positive and -negative cells 
were observed. The neovessels consisted of endothelial marker-
positive cells that were shown in gel matrix. To assess angio-
genesis, the number of migrated cells and neovessels and the 
lengths of neovessels were measured. The number of migrated 
cells was significantly smaller with Vi than with control 
(Figure  4A). The number of neovessels was significantly less 
with Vi treatment than with control (Figure 4B). The length of 
neovessels was significantly shorter with Vi treatment than with 
FigUre 4 | angiogenesis analysis of lectin-stained left ventricular 
wall in three-dimensional culture. The white bar shows the numerical 
values in the control and the black bar shows those in the vasoinhibins 
(Vi)-treated group. The heart segments were treated with VEGF under 
hypoxia in the absence or presence of Vi. The procedures of measuring 
values are described in Section “Materials and Methods.” Vi, vasoinhibin 
100 nM (n = 3, mean ± SEM, *P < 0.05 vs. control). (a) Number of migrated 
cells, (b) number of neovessels, (c) Length of neovessels, and (D) proportion 
of lectin-positive cell.
FigUre 3 | lectin staining of the left ventricular wall in three-
dimensional culture. Lectin staining of the three-dimensional cultured left 
ventricular wall using endothelial cell-specific lectin (green) and DAPI (blue). 
The heart segments were treated with VEGF under hypoxia in the absence or 
presence of Vi. Arrows indicate neovessel and arrow heads indicate migrated 
lectin-positive cell. (a,b) White bar = 200 μm. (c,D) White bar = 100 μm. Vi, 
vasoinhibin 100 nM.
FigUre 2 | effects of vasoinhibins (Vi) on gene expression in 
endothelial cells by real-time Pcr. The white bar shows relative 
expression levels in the control and the black bar shows those in the 
Vi-treated group. eNOS, endothelial nitric oxide synthase; VEGFA, vascular 
endothelial growth factor A; TNF, tumor necrosis factor α; IL6, interleukin 6; 
CASP3, caspase 3; Vi, vasoinhibin 50 nM, N.D., not detectable (n = 3, 
Mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 vs. control).
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control (Figure 4C). The proportion of lectin-positive cells was 
higher with Vi treatment than with control, but not significant 
(P = 0.07, Figure 4D).
DiscUssiOn
In the present study, the anti-angiogenetic effect of Vi in the heart 
was observed. Vi decreased endothelial cell viability in the culture 
experiment, and it decreased expressions of proangiogenic genes, 
such as VEGFA, eNOS, and VE-cadherin. An apoptosis gene, 
CASP3, and inflammatory genes, TNF and IL6, were increased by 
Vi. Furthermore, Vi suppressed cell migration, vascular sprout-
ing, and growth in the three-dimensional left ventricular wall 
angiogenesis assay.
Endothelial cell viability was decreased with Vi. On the other 
hand, Vi did not have any effect on cardiomyocyte viability. The 
endothelial cell is considered the main target cell of Vi because of 
its anti-angiogenetic effect. However, we previously reported that 
Vi had a proapoptotic effect on mammary epithelial cells (10). 
Therefore, Vi would exert effects not only on endothelial cells 
but also other cells. Since cardiomyocyte viability is decreased 
with adenovirus-induced Vi expression (8), the direct effect 
of Vi on cardiomyocyte viability was examined in this study. 
However, there was no obvious effect on its viability in the same 
experimental condition of endothelial cells. At least in part, the 
Vi concentration in media that reduced endothelial cell viability 
might not have been sufficient to decrease cardiomyocyte viabil-
ity. In addition, since the MTS assay may measure not only cell 
viability but also metabolic activity and level of proliferation, 
further experiments would be required.
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Vasoinhibins also altered expressions of genes that partici-
pated in anti-angiogenesis in the present study. Expression levels 
of VEGFA, eNOS, and VE-cadherin were decreased, and levels of 
CASP3 was increased with Vi treatment. Especially, this is the first 
time that Vi are shown to downregulate both VEGF and eNOS 
expression in endothelial cells. VEGF is a potent angiogenic fac-
tor, and its angiogenic function is exerted by binding to VEGF 
receptor. Vi inhibits endothelial cell proliferation that is promoted 
by VEGFA (14). Since VEGF autocrine is necessary to vascular 
homeostasis (15), downregulation of VEGF expression by Vi may 
cause microvascular dysfunction. eNOS is one of the NOS iso-
forms that are constitutively expressed in endothelial cells. Nitric 
oxide, which is produced by eNOS, protects endothelial cells 
against apoptosis and promotes angiogenesis (16), and Vi inhibits 
eNOS activity through dephosphorylation (17). Moreover, Vi 
downregulates expression of inducible NOS, which is another 
NOS isoform (18). Likewise, we found that Vi downregulates 
eNOS expression in endothelial cell culture. VE-cadherin medi-
ates cell adhesion, and is necessary for endothelial survival (19), 
and Vi downregulates the expression of VE-cadherin in the 
present study. In addition, the expression of CASP3, which is a 
key mediator of apoptosis, was increased with Vi treatment, in 
agreement with the previous study (20). These results confirm 
that the Vi also play a role in vascular anti-angiogenesis by the 
apoptotic involvement.
We consider that VEGF-receptor 2 (VEGF-R2) promote 
angiogenesis and Vi prevents its effects. VEGF increasesd eNOS 
expression by binding VEGF-R2 (21). The activation of eNOS was 
induced by increase of intracellular Ca2+ mobilization (22) and 
phosphorylation (23) through VEGF and VEGF-R2. In contrast, 
Vi inhibits both intracellular Ca2+ mobilization (7) and phospho-
rylation of eNOS (17). Moreover, Vi inhibits angiogenesis signal-
ing through inhibiting Ras, which is one of the starting point of 
VEGF signaling (14).
It has been suspected that Vi is also involved to myocarditis, 
which was often observed in PPCM (24). In this study, inflam-
matory cytokines, TNF and IL6, were upregulated by Vi. Vi has a 
pro-inflammatory function via upregulation of intercellular adhe-
sion molecule-1, vascular adhesion molecule-1, and E-selectin 
in endothelial cells (20). Moreover, expression level of eNOS is 
decreased by Vi in present study, and previous study shows that 
Vi inhibits eNOS activity. Since suppression of eNOS activity 
enhances microvascular permeability (25), there is a possibility 
that Vi directly induces myocarditis. In addition, TNF induces 
cardiomyocyte apoptosis (26), and IL6 induces hypertrophy and 
myocardial fibrosis (27). The blood levels of these cytokines were 
higher in PPCM patients (28). Therefore, Vi may cause cardio-
myocyte damage through release of these cytokines, as well as 
microRNA-146a, which is released from endothelial cells by Vi 
and inhibits cardiomyocyte metabolic activity (9).
A previous study reported that left ventricular capillary 
density is decreased in the PPCM mouse model (8). It is known 
that healthy pregnant women develop heart hypertrophy with 
angiogenesis (29). The structural heart change during pregnancy 
is considered to be induced by not only VEGF but also by estrogen 
and cardiac volume overload (29). In this study, left ventricular 
angiogenesis was induced by the hypoxic condition and VEGF 
treatment. This induction of angiogenesis was inhibited by Vi 
treatment in three-dimensional heart culture.
In addition to endothelial cells, migration of non-endothelial 
lectin-negative cell was also observed in heart culture experi-
ments. Thus, Vi may also inhibit migration of cells other than 
endothelial cells, such as pericytes and fibroblasts. Moreover, 
mature vessels that consist of multiple cells were not observed 
with Vi treatment in culture. Since Vi inhibits pericyte migration 
toward endothelial cells and vessel maturation (30), Vi also seems 
to play a inhibiting role in heart vessel maturation.
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